🇺🇸 FDA
Pipeline program

PEMBROLIZUMAB

P160601j

Phase 2 small_molecule active

Quick answer

PEMBROLIZUMAB for Kaposi's sarcoma is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Kaposi's sarcoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials